semaglutide patent expiration 2031 & Tirzepatide Considerations semaglutide patent expiration us 2031

Side effects may include nausea, constipation, and stomach discomfort from bloating

If youre injecting a tirzepatide pen, skip ahead to step 6 after youve performed this step

The greatest growth among GLP-1 receptor agonists in prescriptions for patients with type 1 diabetes occurred with semaglutide (Ozempic/Rybelsus/Wegovy, Novo Nordisk), which rose from 0.2% in 2018 to 4.4% in 2023, whereas tirzepatide (Mounjaro/Zepbound, Eli Lilly) was prescribed in 1.3% of patients with type 1 diabetes in 2023 after being introduced in 2022

Hypoglycaemia risk is generally low in non-diabetic individuals but warrants attention in those on concomitant antidiabetic medications